From September 2018 to March 2020 ObsEva SA (NASDAQ: OBSV) had lost 15.5 points. April of 2020 became a turning point for OBSV to grow sharply until July 2020. Those times the stock could cost around $6 and biotech investors used to spot OBSV in case of any sharp movement.
A catastrophic fall in July to as low as $2.66 has pulled OBSV to trade above $3.00. Thanks to the clinical development program of Yselty which is dedicated to Uterine Fibroids. The testing stage is in phase 3 and has a long time to prep the therapeutic technology to treat the rare disease among women.
Due to the current media update, the stock could actually soar 19%. This could only be the beginning of the OBSV’s rise to recover to $18 value if the program is successful. During the trials, the stock will likely grow with weak volatility on millions of shares daily.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.